NASDAQ:OMCL - Omnicell Stock Price, Forecast & News

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Omnicell, Inc. (NASDAQ:OMCL) released its quarterly earnings results on Thursday, February, 6th. The company reported $0.77 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.78 by $0.01. The firm had revenue of $248.29 million for the quarter, compared to the consensus estimate of $243.69 million. Omnicell had a net margin of 6.84% and a return on equity of 11.76%. The company's revenue for the quarter was up 17.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.70 earnings per share. View Omnicell's Earnings History.

Omnicell is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Omnicell.

Omnicell issued an update on its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of $2.96-3.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.00. The company issued revenue guidance of $1.00-1.02 billion, compared to the consensus revenue estimate of $991.00 million.

7 brokerages have issued 12-month price objectives for Omnicell's stock. Their forecasts range from $82.00 to $100.00. On average, they expect Omnicell's share price to reach $89.29 in the next twelve months. This suggests a possible upside of 9.5% from the stock's current price. View Analyst Price Targets for Omnicell.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.

Media coverage about OMCL stock has trended somewhat negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Omnicell earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Omnicell.

Omnicell saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 2,070,000 shares, a decrease of 5.9% from the January 15th total of 2,200,000 shares. Based on an average trading volume of 229,000 shares, the short-interest ratio is presently 9.0 days. Approximately 5.0% of the company's shares are sold short. View Omnicell's Current Options Chain.

Some companies that are related to Omnicell include Cerner (CERN), HMS (HMSY), Cortexyme (CRTX), Allscripts Healthcare Solutions (MDRX), Vocera Communications (VCRA), HealthStream (HSTM) and Computer Programs & Systems (CPSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), Netflix (NFLX), AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Adobe (ADBE), Micron Technology (MU), Alibaba Group (BABA), Bank of America (BAC) and Gilead Sciences (GILD).

Omnicell's stock is owned by a number of of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (3.76%), Credit Suisse AG (3.51%), State Street Corp (2.88%), Eagle Asset Management Inc. (2.00%), Janus Henderson Group PLC (1.65%) and Geode Capital Management LLC (1.37%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View Institutional Ownership Trends for Omnicell.

OMCL stock was sold by a variety of institutional investors in the last quarter, including Braun Stacey Associates Inc., Redwood Investments LLC, AQR Capital Management LLC, PNC Financial Services Group Inc., Charles Schwab Investment Management Inc., Falcon Point Capital LLC, Westwood Holdings Group Inc. and First Trust Advisors LP. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Scott Peter Seidelmann. View Insider Buying and Selling for Omnicell.

OMCL stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Credit Suisse AG, Trillium Asset Management LLC, Bank of America Corp DE, WCM Investment Management LLC, Great West Life Assurance Co. Can, Summit Creek Advisors LLC and Fiera Capital Corp. View Insider Buying and Selling for Omnicell.

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OMCL stock can currently be purchased for approximately $81.52.

Omnicell has a market capitalization of $3.42 billion and generates $897.03 million in revenue each year. The company earns $61.34 million in net income (profit) each year or $2.19 on an earnings per share basis. Omnicell employs 2,480 workers across the globe.View Additional Information About Omnicell.

The official website for Omnicell is http://www.omnicell.com/.

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]